- Home
- ATOS vs AEYE Comparison
ATOS vs AEYE Comparison
Compare ATOS & AEYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- AEYE
- Stock Information
- Founded
- ATOS 2009
- AEYE 2005
- Country
- ATOS United States
- AEYE United States
- Employees
- ATOS N/A
- AEYE N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- AEYE Computer Software: Prepackaged Software
- Sector
- ATOS Health Care
- AEYE Technology
- Exchange
- ATOS Nasdaq
- AEYE Nasdaq
- Market Cap
- ATOS 130.5M
- AEYE 154.6M
- IPO Year
- ATOS 2012
- AEYE N/A
- Fundamental
- Price
- ATOS $0.98
- AEYE $13.84
- Analyst Decision
- ATOS Strong Buy
- AEYE Strong Buy
- Analyst Count
- ATOS 3
- AEYE 4
- Target Price
- ATOS $6.25
- AEYE $25.25
- AVG Volume (30 Days)
- ATOS 1.3M
- AEYE 92.2K
- Earning Date
- ATOS 11-11-2025
- AEYE 11-06-2025
- Dividend Yield
- ATOS N/A
- AEYE N/A
- EPS Growth
- ATOS N/A
- AEYE N/A
- EPS
- ATOS N/A
- AEYE N/A
- Revenue
- ATOS N/A
- AEYE $38,238,000.00
- Revenue This Year
- ATOS N/A
- AEYE $17.16
- Revenue Next Year
- ATOS N/A
- AEYE $14.79
- P/E Ratio
- ATOS N/A
- AEYE N/A
- Revenue Growth
- ATOS N/A
- AEYE 18.53
- 52 Week Low
- ATOS $0.55
- AEYE $8.91
- 52 Week High
- ATOS $1.66
- AEYE $34.85
- Technical
- Relative Strength Index (RSI)
- ATOS 57.15
- AEYE 53.72
- Support Level
- ATOS $0.86
- AEYE $13.62
- Resistance Level
- ATOS $1.29
- AEYE $15.44
- Average True Range (ATR)
- ATOS 0.08
- AEYE 0.69
- MACD
- ATOS 0.01
- AEYE -0.09
- Stochastic Oscillator
- ATOS 38.23
- AEYE 40.16
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.